[go: up one dir, main page]

MA28758B1 - Composes d'aminoalkylglucosaminide phosphate et leur utilisation - Google Patents

Composes d'aminoalkylglucosaminide phosphate et leur utilisation

Info

Publication number
MA28758B1
MA28758B1 MA29644A MA29644A MA28758B1 MA 28758 B1 MA28758 B1 MA 28758B1 MA 29644 A MA29644 A MA 29644A MA 29644 A MA29644 A MA 29644A MA 28758 B1 MA28758 B1 MA 28758B1
Authority
MA
Morocco
Prior art keywords
phosphate compounds
aminoalkylglucosaminide
aminoalkylglucosaminide phosphate
compounds
phosphate
Prior art date
Application number
MA29644A
Other languages
English (en)
Inventor
David A Johnson
David H Persing
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of MA28758B1 publication Critical patent/MA28758B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Lift-Guide Devices, And Elevator Ropes And Cables (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA29644A 2004-07-08 2007-01-31 Composes d'aminoalkylglucosaminide phosphate et leur utilisation MA28758B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/888,683 US7960522B2 (en) 2003-01-06 2004-07-08 Certain aminoalkyl glucosaminide phosphate compounds and their use

Publications (1)

Publication Number Publication Date
MA28758B1 true MA28758B1 (fr) 2007-07-02

Family

ID=35839700

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29644A MA28758B1 (fr) 2004-07-08 2007-01-31 Composes d'aminoalkylglucosaminide phosphate et leur utilisation

Country Status (24)

Country Link
US (2) US7960522B2 (fr)
EP (2) EP2940027A1 (fr)
JP (1) JP2008505897A (fr)
CN (1) CN101010328A (fr)
AU (1) AU2005272076B2 (fr)
BR (1) BRPI0513144A (fr)
CA (1) CA2573059A1 (fr)
CY (1) CY1116571T1 (fr)
DK (1) DK1776375T3 (fr)
ES (1) ES2541306T3 (fr)
HK (2) HK1099308A1 (fr)
HU (1) HUE025324T2 (fr)
IL (1) IL180599A (fr)
MA (1) MA28758B1 (fr)
MX (1) MX2007000331A (fr)
NO (1) NO340869B1 (fr)
NZ (1) NZ552790A (fr)
PL (1) PL1776375T3 (fr)
PT (1) PT1776375E (fr)
RU (1) RU2007104781A (fr)
SI (1) SI1776375T1 (fr)
TR (1) TR200701350T1 (fr)
WO (1) WO2006016997A2 (fr)
ZA (2) ZA200700996B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
BRPI0911195A2 (pt) 2008-04-09 2017-06-20 The Univ Of North Caroline At Chapel Hill métodos de regulação de arranjo de citoesqueleto de actina e formação de gap intracelular
ES2552243T3 (es) * 2008-12-23 2015-11-26 Glaxosmithkline Biologicals S.A. Miméticos del lípido A para su uso en la inducción de una respuesta inmunitaria
EA201101349A1 (ru) * 2009-04-09 2012-05-30 Университет Северной Каролины В Чапел-Хилл Методы лечения отека, связанного с ишемией-реперфузией
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
GB201101331D0 (en) * 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
BR112015023502A2 (pt) 2013-03-15 2017-07-18 Glaxosmithkline Biologicals Sa composição, e, métodos para intensificar uma resposta imune e melhorar ou prevenir substancialmente uma doença infecciosa, uma doença autoimune, ou uma condição alérgica em um indivíduo
EP3556353A3 (fr) 2014-02-25 2020-03-18 Merck Sharp & Dohme Corp. Adjuvants de vaccins à nanoparticules lipidiques et systèmes d'administration d'antigènes
CA2942235A1 (fr) 2014-03-12 2015-09-17 Glaxosmithkline Biologicals S.A. Formulation liposomale immunogene
CN106456546A (zh) 2014-03-12 2017-02-22 葛兰素史密丝克莱恩生物有限公司 用于黏膜递送的脂质体组合物
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
WO2016198621A1 (fr) 2015-06-12 2016-12-15 Glaxosmithkline Biologicals Sa Polypeptides et polynucléotides d'adénovirus
WO2017013603A1 (fr) 2015-07-21 2017-01-26 Glaxosmithkline Biologicals Sa Immunothérapie complémentaire pour la prévention ou le traitement d'une maladie infectieuse
WO2017021792A1 (fr) * 2015-08-06 2017-02-09 Glaxosmithkline Biologicals Sa Agonistes de tlr4, leurs compositions et leur utilisation dans le traitement du cancer
TW201716084A (zh) * 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
WO2017021912A1 (fr) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Modulateurs de tlr combinés avec anticorps anti-ox40
EP3322713B1 (fr) 2015-12-03 2021-01-20 GlaxoSmithKline Intellectual Property Development Limited Dinucléotides cycliques de purine à titre de modulateurs du sting
WO2017098421A1 (fr) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Composés benzothiadiazine
WO2017153952A1 (fr) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited Dérivés de 5-sulfamoyl-2-hydroxybenzamide
UY37195A (es) 2016-04-07 2017-10-31 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas
SG11201808708RA (en) 2016-04-07 2018-11-29 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
JP2019516685A (ja) 2016-05-05 2019-06-20 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｚｅｓｔｅホモログ２阻害剤のエンハンサー
CA3031047A1 (fr) 2016-07-20 2018-01-25 Glaxosmithkline Intellectual Property Development Limited Derives d'isoquinoleine utilises comme inhibiteurs de perk
US20190365710A1 (en) 2016-12-01 2019-12-05 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2019021208A1 (fr) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Dérivés d'indazole utiles en tant qu'inhibiteurs de perk
WO2019053617A1 (fr) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Composés chimiques
TW201927771A (zh) 2017-10-05 2019-07-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 可作為蛋白質調節劑之雜環醯胺及其使用方法
BR112020006780A2 (pt) 2017-10-05 2020-10-06 Glaxosmithkline Intellectual Property Development Limited moduladores do estimulador de genes do interferon (sting)
EP3752182B1 (fr) 2018-02-12 2024-05-15 Inimmune Corporation Ligands du récepteur de type toll
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
WO2020007760A1 (fr) 2018-07-03 2020-01-09 Glaxosmithkline Intellectual Property Development Limited Composés tlr4 ou sels pharmaceutiquement acceptables de ceux-ci, compositions ou formulations pharmaceutiques correspondantes, procédés de préparation, traitement ou utilisations
WO2020030571A1 (fr) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinaisons d'un anticorps pd-1 et d'un modulateur de tlr4 et leurs utilisations
WO2020030570A1 (fr) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinaisons d'un anticorps ox40 et d'un modulateur de tlr4 et leurs utilisations
WO2020031087A1 (fr) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Polythérapie
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
AU2020278777A1 (en) 2019-05-23 2021-12-16 The University Of Montana Vaccine adjuvants based on TLR receptor ligands
CN114222760A (zh) 2019-06-26 2022-03-22 葛兰素史密斯克莱知识产权发展有限公司 Il1rap结合蛋白
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CA3146900A1 (fr) 2019-07-21 2021-01-28 Glaxosmithkline Biologicals Sa Vaccin viral therapeutique
WO2021018941A1 (fr) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Méthodes de traitement du cancer
WO2021043961A1 (fr) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Schéma posologique pour le traitement du cancer avec un anticorps agoniste anti-icos et une chimiothérapie
MX2022002823A (es) 2019-09-09 2022-10-21 Glaxosmithkline Biologicals Sa Composiciones inmunoterapeuticas.
WO2021058711A2 (fr) 2019-09-27 2021-04-01 Glaxosmithkline Intellectual Property Development Limited Protéines de liaison à un antigène
CA3164751A1 (fr) 2019-12-18 2021-06-24 Benjamin Joseph MORROW Composes
EP4161570A1 (fr) 2020-06-05 2023-04-12 GlaxoSmithKline Biologicals S.A. Protéines modifiées de spicule de coronavirus bêta
JP2023542141A (ja) 2020-09-15 2023-10-05 ザ ユニバーシティー オブ モンタナ 繊維状バクテリオファージを標的化する組成物および方法
US20240002425A1 (en) * 2020-11-11 2024-01-04 Daiichi Sankyo Company, Limited Novel aminoalkyl glucosaminide 4-phosphate derivative
EP4032547A1 (fr) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Fragments dérivés du hsv 1 fce pour le traitement du hsv
CN116917273A (zh) 2021-03-02 2023-10-20 葛兰素史克知识产权发展有限公司 作为dnmt1抑制剂的经取代的吡啶
WO2022208353A1 (fr) 2021-03-31 2022-10-06 Glaxosmithkline Intellectual Property Development Limited Protéines de liaison à l'antigène et leurs combinaisons

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
DE10399031I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
WO1989001973A2 (fr) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Virus variolique recombinant d'immunisation contre des antigenes associes a une tumeur
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
ATE92538T1 (de) 1988-01-21 1993-08-15 Genentech Inc Verstaerkung und nachweis von nukleinsaeuresequenzen.
CA1340807C (fr) 1988-02-24 1999-11-02 Lawrence T. Malek Procede d'amplification d'une sequence d'acide nucleique
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
CA2066053C (fr) 1989-08-18 2001-12-11 Harry E. Gruber Retrovirus recombinants livrant des constructeurs de vecteur aux cellules cibles
KR920007887B1 (ko) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 내연기관의 배기가스 정화장치
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
EP0550436A1 (fr) 1989-11-06 1993-07-14 Alkermes Controlled Therapeutics, Inc. Microspheres de proteines et leurs procedes d'utilisation
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
JPH05503841A (ja) 1989-11-16 1993-06-24 デューク ユニバーシティ 動物組織細胞の微片仲介トランスフォーメーション
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
US5530113A (en) 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
HK1013804A1 (en) 1994-01-21 1999-09-10 Powderject Vaccines Inc Gas driven gene delivery instrument
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
CA2220530A1 (fr) 1995-06-02 1996-12-05 Incyte Pharmaceuticals, Inc. Procede ameliore pour obtenir des sequences d'adn complementaire longues
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
CA2230494A1 (fr) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition se pretant a la liberation prolongee d'un agent
US6506792B1 (en) 1997-03-04 2003-01-14 Sterix Limited Compounds that inhibit oestrone sulphatase and/or aromatase and methods for making and using
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7541020B2 (en) 1997-05-08 2009-06-02 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US7063967B2 (en) 1997-05-08 2006-06-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) * 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
KR100241901B1 (ko) 1997-08-28 2000-02-01 윤종용 핸드셋과 핸즈프리킷 공용 음성인식기의 등록 엔트리 관리방법
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
TR200002930T2 (tr) 1998-04-09 2000-12-21 Smithkline Beecham Biologicals S.A. Kolaylaştırıcı kompozisyonlar
US6355251B1 (en) 1999-06-15 2002-03-12 Mark Zamoyski Compositions and methods for epidermal chemexfoliation
JP2003514824A (ja) * 1999-11-15 2003-04-22 ビオミラ，インコーポレーテッド 合成脂質−ａ類似体およびその使用
US6699846B2 (en) 2000-03-17 2004-03-02 Corixa Corporation Mono- and disaccharides for the treatment of nitric oxide related disorders
AU6969501A (en) 2000-05-19 2001-12-03 Corixa Corp Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
ATE321063T1 (de) 2000-08-04 2006-04-15 Corixa Corp Neue immunoeffectorverbindungen
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US7030094B2 (en) 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US7288640B2 (en) * 2002-07-08 2007-10-30 Corixa Corporation Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
RU2340621C2 (ru) 2002-07-08 2008-12-10 Корикса Корпорейшн Способы получения аминоалкилглюкозаминидфосфатов и дисахаридных иммуноэффекторов и их промежуточных соединений
WO2004062599A2 (fr) 2003-01-06 2004-07-29 Corixa Corporation Composes d'aminoalkyle glucosaminide phosphate et leur utilisation
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
CY1116571T1 (el) 2017-03-15
AU2005272076A2 (en) 2006-02-16
CA2573059A1 (fr) 2006-02-16
JP2008505897A (ja) 2008-02-28
US20050227943A1 (en) 2005-10-13
WO2006016997A2 (fr) 2006-02-16
US20120058148A1 (en) 2012-03-08
PL1776375T3 (pl) 2015-08-31
AU2005272076A1 (en) 2006-02-16
BRPI0513144A (pt) 2008-04-29
CN101010328A (zh) 2007-08-01
SI1776375T1 (sl) 2015-11-30
DK1776375T3 (en) 2015-07-13
MX2007000331A (es) 2007-03-12
TR200701350T1 (tr) 2007-05-21
NO340869B1 (no) 2017-07-03
EP2940027A1 (fr) 2015-11-04
IL180599A (en) 2011-11-30
IL180599A0 (en) 2008-03-20
NO20070699L (no) 2007-04-03
HK1099308A1 (en) 2007-08-10
NZ552790A (en) 2010-11-26
ZA200804906B (en) 2009-11-25
ZA200700996B (en) 2008-12-31
AU2005272076B2 (en) 2011-09-22
EP1776375B1 (fr) 2015-04-01
RU2007104781A (ru) 2008-08-27
PT1776375E (pt) 2015-08-20
US7960522B2 (en) 2011-06-14
WO2006016997A3 (fr) 2006-12-07
HUE025324T2 (en) 2016-01-28
ES2541306T3 (es) 2015-07-17
EP1776375A2 (fr) 2007-04-25
HK1217105A1 (zh) 2016-12-23

Similar Documents

Publication Publication Date Title
MA28758B1 (fr) Composes d'aminoalkylglucosaminide phosphate et leur utilisation
FR21C1056I2 (fr) Composes de thienopyrimidine et utilisation
EP1831207A4 (fr) Composes d'aminopyrimidine et procedes d'utilisation correspondants
EP1744744A4 (fr) Composes bioactifs et procedes de leur utilisation
FR12C0019I1 (fr) O-cyclopropyle-carboxanilides et leur utilisation comme fongicides
EP1812102A4 (fr) Endoprothese occlusale et procedes d'utilisation associes
EP1838331A4 (fr) Peptides antimicrobiens et procedes d'utilisation associes
EP1624935A4 (fr) Composites anti-adherence et methodes d'utilisation desdits composites
MA29029B1 (fr) Composes de thiadiazole et leurs procedes d'utilisation
EP1943507A4 (fr) Detecteur de nox et procedes d'utilisation associes
EP1827289A4 (fr) Implant et element d'implant
MA29014B1 (fr) Formulations d'anticorps
MA30684B1 (fr) Anticorps anti-mn et leurs procedes d'utilisation.
EP1677822A4 (fr) 4'-thionucleosides et composes d' oligomeres
EP1720766A4 (fr) Soute d'aeronef
EP1913112A4 (fr) Agent de soutenement et procedes d'utilisation
EP1940466A4 (fr) Anticorps monoclonal anti-addl et leur utilisation
EP1706791A4 (fr) Compositions de photoresines et leurs procedes d'utilisation
EP1731506A4 (fr) Derives de 5-hydroxyindol-3-carboxylate et leur utilisation
FR2866955B1 (fr) Detecteur d'humidite de type capacitif
EP1638977A4 (fr) Salinosporamides et leurs methodes d'utilisation
EP1841581A4 (fr) Composites et procedes de fabrication et d'utilisation correspondants
EP1928496A4 (fr) Antagonistes de c/clp et leurs methodes d'utilisation
EP1863769A4 (fr) Inhibiteurs hsp90, procedes de realisation et d'utilisation correspondants
EP1735456A4 (fr) Compositions poylmeres et procedes associes d'utilisation